The joint prevention and control mechanism of the State Council held a press conference on the morning of the 19th to introduce the vaccination of key populations against COVID-19.
Zheng Zhongwei, director of the Medical and Health Science and Technology Development Research Center of the National Health Commission, said that so far, according to the statistics of the World Health Organization, China’s vaccines entering clinical trials and phase III clinical vaccines are in the first phalanx in the world.
China’s COVID-19 vaccine research and development level is at the forefront of the world and has sufficient production and self-sufficiency, but it still joins the COVID-19 vaccine implementation plan, which aims to promote the equitable distribution of vaccines, ensure the availability of vaccines to developing countries, and drive more countries with a position to do so to join and support the Implementation Plan. .”
Many countries around the world have voted for the safety and effectiveness of China’s COVID-19 vaccine.
Recently, 50,000 Chinese-made COVID-19 vaccines arrived in Egypt.
The vaccines have been urgently approved by the World Health Organization and will be prioritized for vaccination by medical personnel and vulnerable people vulnerable to the threat of COVID-19 infection.
Egypt’s Minister of Health and Population, Khalai, said: “Thank you to the Chinese government and people for their support for Egypt’s access to vaccines.
This batch of vaccines has previously undergone a third phase of clinical trial in Egypt, and I am honored to participate in this trial myself.
The Chinese vaccines also made Egypt the first African country to receive a coronavirus vaccine.”
The Egyptian Ministry of Health said in a statement recently released that the mid-term analysis of the data of the last clinical trial of the vaccine in China shows that the total effectiveness rate of the vaccine is 86%, of which “the serum conversion rate of neutralizing antibodies reaches 99%, and the effectiveness of preventing moderate and severe symptoms is 100%”.
On the 15th local time, Amal Fatah, a senior official of the Sudanese Ministry of Health, said that according to research and recommendations from relevant scientific institutions, the Sudanese government has ordered 8.4 million doses of COVID-19 through the Global Alliance for Vaccines and Immunization, which are expected to arrive in the Sudan in the first quarter of next year.
Among these vaccines, she said, the vaccine produced by China will be Sudan’s first choice, because China’s vaccine is the safest and tested the most.
United Arab Emirates ·
The International Clinical Phase III Trial of the COVID-19 Inactivated Vaccine of China National Pharmaceutical Group was launched in Abu Dhabi, United Arab Emirates on June 23. More than 30,000 volunteers from 125 countries and regions living in the United Arab Emirates participated in the experiment.
On September 14, the UAE government approved the emergency use of the COVID-19 inactivated vaccine of China National Pharmaceutical Group for local front-line medical workers.
On December 9, the United Arab Emirates approved the official registration of the inactivated vaccine for the novel coronavirus developed by China National Pharmaceutical Group.
On December 13th local time, Bahrain’s National Health Supervision and Administration announced that it had officially approved the registration and listing of the inactivated coronavirus vaccine developed by China National Pharmaceutical Group in Bahrain.
The results of the international clinical trial of the vaccine show that after testing 42,299 inoculated volunteers, the vaccine has an effective rate of 86% and a seroconversion rate of 99% for comprehensive antibodies, which can prevent the conversion of mild COVID-19 to moderate and severe.
According to Indonesia’s Compass, the first 1.2 million doses of vaccine from China arrived in Jakarta, the Indonesian capital, on the evening of December 6.
Indonesian President Joko said that the coronavirus vaccine from China was good news for the Indonesian people.
On November 19, the first batch of 120,000 doses of COVID-19 developed by China arrived in Brazil.
The governor of São Paulo, Brazil, revealed that according to the cooperation agreement with China, Brazil’s Butantan Institute will receive 6 million doses of Chinese coronavirus vaccine and 40 million doses of raw materials for the production of COVID-19 vaccine by the end of this year.
As a responsible power that keeps its promise, while continuing to do a good job in the normal epidemic prevention and control work, China has also played an important role in promoting the international community to fight the epidemic together, providing valuable anti-epidemic experience for many countries and regions.
Pakistani President Arif Alvi said in an exclusive interview with the reporter of China Main Station on the 14th of this month that it is precisely because of learning from China’s anti-epidemic experience that Pakistan has successfully controlled the incidence of COVID-19 to a low level.
He also expressed high praise for China’s control of the epidemic in a short time.
“I think China has made great efforts to contain the COVID-19 pandemic, and history will prove it.
China, as a big country, has been under control of the pandemic in a month or two, and it is still well controlled today.
Guo Xiangang, a researcher at the China Institute of International Studies, said that China has joined hands with other countries to strengthen scientific research cooperation in traceability, drugs, vaccines, testing and other aspects, which has provided strong support for epidemic prevention and control and won wide praise from the international community.
In addition to doing its own anti-epidemic work, China has also extended a helping hand to other countries.
While the epidemic in China was still relatively serious, China sent medical teams to other countries, especially some developing countries.
China’s efforts to help other countries fight the pandemic have also received strong praise from the world, reflecting a high level of international humanitarianism.”
Zheng Zhongwei, head of the special working group of vaccine research and development of the scientific research and control mechanism of the Joint Prevention and Control Mechanism of the State Council and director of the Medical and Health Science and Technology Development Research Center of the National Health Commission, said recently that China’s COVID-19 vaccine research and development has entered the sprint stage and is preparing for large-scale production.
Wang Wenbin, spokesman of China’s Ministry of Foreign Affairs, said on the 15th of this month that after China’s vaccine research and development is completed and put into use, it will make Chinese contributions to achieving the accessibility and affordability of vaccines in developing countries as a global public good.